{
    "nctId": "NCT04891731",
    "briefTitle": "Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast Cancer",
    "officialTitle": "Efficacy and Safety of Leuprorelin Acetate Every-3-months Depot Plus an Aromatase Inhibitor or Tamoxifen in Premenopausal Women With Hormone Receptor-positive Breast Cancer: a Clinical Prospective Observational Study",
    "overallStatus": "UNKNOWN",
    "conditions": "Hormone Receptor-positive Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 120,
    "primaryOutcomeMeasure": "the suppression proportion of serum estradiol (E2)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. age\u226518 years;\n2. Tumor that expressed ER or progesterone receptor in at least 10% of the cells, as assessed by immunohistochemical testing\n3. T1 to T3, any N, and M0, according to the TNM classification\n4. Any type of breast surgical procedure\n5. Any type of preoperative and/or postoperative adjuvant chemotherapy prior to enrollment\n6. Capable of receiving the study drug within 12 weeks after surgery or after postoperative chemotherapy completion prior to enrollment\n7. Eastern Cooperative Oncology Group performance status of Grade 0 or 1\n\nExclusion Criteria:\n\n1. Bilateral oophorectomy or ovarian irradiation\n2. No use of other OFS drugs",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}